Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: The ACTION trial

Journal of Hypertension

Volumn 23, Issue 3, 2005, Pages 641-648

  Lubsen, Jacobus ^a,b   Wagener, Gilbert ^c   Kirwan, Bridget Anne ^a   De Brouwer, Sophie ^a   Poole Wilson, Philip A ^d  

^a SOCAR RESEARCH SA   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c BAYER PHARMA AG   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angina pectoris; Coronary artery disease; Nifedipine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LONG ACTING DRUG; NIFEDIPINE; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SMOKING; STABLE ANGINA PECTORIS; STATISTICAL ANALYSIS; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 18844379931     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000160223.94220.29     Document Type: Article

References (26)

1. World Health Organization. World health report 2003. Geneva, Switzerland: WHO; 2003.
2. American Heart Association. Heart disease and stroke statistics - 2003 Update. Dallas, Texas: American Heart Association; 2002.
3. Management Committee of the Australian National Blood Pressure Study. The Australian therapeutic trial in mild hypertension. Lancet 1980; 1:1261-1267.
4. MRC Working Party. Medical Research Council trial of treatment of mild hypertension: principle results. BMJ 1985; 291:97-104.
5. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1:1349-1354.
6. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in old patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
7. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304:405-413.
8. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
9. Staessen JA, Fagard RH, Thijs L, Delis H, Arabidze GG, Birkenhaeger WH, et al. Randomised, double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
10. Brown MJ, Palmer CR, Castaigne A, Leeuw PW de, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel-blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal of hypertension treatment (INSIGHT). Lancet 2000; 356:366-372.
11. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old patients with Hyertension-2 study. Lancet 1999; 354:1751-1756.
12. Hanson L, Hedner T, Lund-Johanson P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonist therapy compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
13. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
14. Poole-Wilson PA, Lubsen J, Kirwan BA, Dalen FJ van, Wagener G, Danchin N, et al. A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849-857.
15. Lubsen J, Poole-Wilson PA, Pocock SJ, Dalen FJ van, Baumann J, Kirwan BA, et al. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Eur Heart J 1998; 19(suppl):120-132.
16. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet 1995; 346:586-587.
17. Opie LH. Risks and benefits of calcium antagonists. Lancet 1995; 346:961.
18. Dens JA, Desmet WJ, Coussement P, Scheerder IK De, Kostopoulos K, Kerdsinchai P, et al. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart 2003; 89:887-892.
19. EUROpean trial on reduction of cardiac events with perindopril in stable coronary artery disease. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
20. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Nikutta P, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the international nifedipine trial on antiatherosclerotic therapy (INTACT) Lancet 1990; 335:1109-1113.
21. Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37:1410-1413.
22. Boersma E, Keil U, Bacquer D De, Backer G De, Pyorala K, Poldermans D, et al. Blood pressure is insufficiently controlled in European patients with established coronary artery disease. J Hypertens 2003; 21:1831-1840.
23. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1:581-584.
24. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
26. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21:1779-1786.